DSpace width= university logo mark
Japanese | English 

KURA > C. 医薬保健学域・研究域/医・薬学部/医学系研究科 > c10. 学術雑誌掲載論文(医・保健) > 1. 査読済論文(医学・保健) >


ファイル 記述 サイズフォーマット
ME-PR-NAMIKI-M-303.pdf290.02 kBAdobe PDF
タイトル: Primary combined androgen blockade in localized disease and its mechanism
著者: Namiki, Mikio link image
Kitagawa, Yasuhide link image
Mizokami, Atsushi link image link image
Koh, Eitetsu link image
並木, 幹夫
北川, 育秀
溝上, 敦
髙, 榮哲
発行日: 2008年 4月
出版社(者): Elsevier
雑誌名: Best Practice and Research in Clinical Endocrinology and Metabolism
ISSN: 1521-690X
巻: 22
号: 2
開始ページ: 303
終了ページ: 315
キーワード: D'Amico risk grouping
localized and locally advanced prostate cancer
primary androgen deprivation
primary combined androgen blockade
抄録: In spite of clinical practice guidelines such as NCI-PDQ - in which primary androgen deprivation therapy (PADT) is not recommended as the primary treatment for localized prostate cancer - many patients have been treated with PADT. One of the reasons is that urologists themselves permit patients' desire because they know the effectiveness of PADT for some patients in their experiences. In this review we demonstrate basic mechanisms and the clinical efficacy of primary combined androgen blockade (PCAB) for localized or locally advanced prostate cancer. Then we discuss which patients are candidates for PCAB, and show that more than 30% of low- or intermediate-risk localized prostate cancers could be controlled in the long term with only PCAB. Short-term or intermittent PADT could not be recommended because of the possibilities of changing the character of the cancer cells by incomplete androgen ablation. We propose algorithms for the treatment of localized prostate cancer not only in low- and intermediate-risk groups but also in the high-risk group. © 2008.
DOI: 10.1016/j.beem.2008.01.007
URI: http://hdl.handle.net/2297/9941
資料種別: Journal Article
版表示: author
出現コレクション:1. 査読済論文(医学・保健)

このアイテムを引用あるいはリンクする場合は次の識別子を使用してください。 http://hdl.handle.net/2297/9941



Valid XHTML 1.0! DSpace Software Copyright © 2002-2010  Duraspace - ご意見をお寄せください